ARTICLE | Company News
C2N Diagnostics, AbbVie deal
April 13, 2015 7:00 AM UTC
C2N granted AbbVie an exclusive, worldwide license to develop and commercialize a portfolio of antibodies against microtubule-associated protein tau (tau; MAPT; FTDP-17) to treat Alzheimer’s disease...